CARDIFF, Calif., March 4, 2025 /PRNewswire/ -- Care Solace, the leading provider of mental health care coordination services for K-12…
Conference call will be held on Tuesday, March 11 at 9:00 a.m. ET CARMEL, Ind., March 4, 2025 /PRNewswire/ --…
WELL announces it has added 11 clinics to its Canadian Clinics network since February 1, 2025. This included 9 acquired…
Advanced Testing with a Reduced Wait Time SAN DIEGO, March 3, 2025 /PRNewswire/ -- Foresight Psychology, a leading provider of…
Boston, March 3, 2025 /PRNewswire/ -- Advanced Brain Methodologies Inc. (ABM) a division of Primary & Preventive Care Inc., has…
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,…
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of…
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical TrialsHOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology,…
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney…